Fanti, StefanoBrigantii, AlbertoEmmett, LouiseFizazi , KarimGillessen, SilkeGoffin, KarolienHadaschik, Boris AHerrmann, KenKunikowska, JolantaMaurer, TobiasMacLennan, StevenMottet, NicolasMurphy, Declan GOprea-Lager, Daniela E.O’Sullivan, Joe MOyen, Wim JGRouvière, OlivierSartor, OliverStenzl, ArnulfVan Poppel, HendrikWalz, JochenWitjes, WimBjartell, Anders2023-02-162023-02-162022-10-01Fanti, S, Brigantii, A, Emmett, L, Fizazi , K, Gillessen, S, Goffin, K, Hadaschik, B A, Herrmann, K, Kunikowska, J, Maurer, T, MacLennan, S, Mottet, N, Murphy, D G, Oprea-Lager, D E, O’Sullivan, J M, Oyen, W JG, Rouvière, O, Sartor, O, Stenzl, A, Van Poppel, H, Walz, J, Witjes, W & Bjartell, A 2022, 'EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [177Lu]Lu-PSMA Radioligand Therapy', European Urology Oncology, vol. 5, no. 5, pp. 530-536. https://doi.org/10.1016/j.euo.2022.05.0032588-9311ORCID: /0000-0002-2691-8421/work/114480386https://hdl.handle.net/2164/20070Funding support and role of sponsor: The EAU/EANM PSMA-based imaging and therapy consensus meeting was supported by an unrestricted educational grant from Novartis; Novartis had no influence over the content of the meeting or the publication. Medical writing support was funded by the European Association of Urology Research Foundation. Acknowledgements: The authors acknowledge Emily Spieker (Management Assistant, European Association of Urology) for project management. Medical writing support was provided by Angela Corstorphine of Kstorfin Medical Communications (KMC) limited.72699031556571engSDG 3 - Good Health and Well-beingComputed tomographyConsensusDiagnosisLutetiumPatient selectionPositron emission tomographyProstate cancerPSMARadioactive tracerTherapyProstate-specific membrane antigenR MedicineRJournal article10.1016/j.euo.2022.05.003http://www.scopus.com/inward/record.url?scp=85139488755&partnerID=8YFLogxK55